Rut Tejero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rut Tejero has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Alfons Navarro
Departamento Biología Vegetal, Facultad de Biología, CEIR Campus Mare Nostrum (CMN), Universidad de Murcia, Murcia, Spain
11 shared publications - Mariano Monzo
University of Barcelona
8 shared publications - Gerardo Ferrer
Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
6 shared publications Alfons Navarro
Facultat de Medicina, Universitat de Barcelona
5 shared publicationsCarmen Muñoz
Facultat de Medicina, Universitat de Barcelona
5 shared publicationsNuria Viñolas
Oncology, Hospital Clínic
5 shared publications
Latest Publications
- Open Access
Plexin-B2 is a key regulator of cell mechanics during multicellular organization
SUMMARY: During multicellular organization, individual cells need to constantly respond to environmental cues and adjust contractile and adhesive forces in order to maintain tissue integrity. The signaling pathways linking biochemical cues and tissue mechanics are unclear. Here, we show that Plexin-B2 regulates mechanochemical integration during multicellular organization. In human embryonic stem cells (hESCs), Plexin-B2 controls cell shape and tissue geometry in both 2D epithelial colony and 3D spheroid aggregates by regulating actomyosin contractility and junctional/cell-matrix adhesive properties. Atomic force microscopy (AFM) directly demonstrates that Plexin-B2 modulates cell stiffness in hESC colonies, which in turn impacts cell proliferation and cell fate specification through β-catenin signaling and YAP mechanosensing. YAP also functions as a mechanoregulator downstream of Plexin-B2, thus forming a mechanochemical integrative loop. In human neuroprogenitor cells (hNPCs), Plexin-B2 similarly controls cell stiffness and tensile forces, as revealed by AFM and FRET tension sensor studies. Strikingly, Plexin-B2-deficient hNPCs display accelerated neuronal differentiation. From an organogenesis perspective, Plexin-B2 maintains cytoarchitectural integrity of neuroepithelium, as modeled in cerebral organoids. On a signaling level, Plexin-B2 engages extracellular as well as intracellular Ras-GAP and RBD domains for mechanoregulation through Rap and Rac GTPases. Our data unveil a fundamental function of Plexin-B2 for mechanochemical integration during multicellular organization, and shed light on the principle of force-mediated regulation of stem cell biology and tissue morphogenesis.
Open AccessPlexin-B2 is a key regulator of cell mechanics during multicellular organization
SUMMARY: During multicellular organization, individual cells need to constantly respond to environmental cues and adjust contractile and adhesive forces in order to maintain tissue integrity. The signaling pathways linking biochemical cues and tissue mechanics are unclear. Here, we show that Plexin-B2 regulates mechanochemical integration during multicellular organization. In human embryonic stem cells (hESCs), Plexin-B2 controls cell shape and tissue geometry in both 2D epithelial colony and 3D spheroid aggregates by regulating actomyosin contractility and junctional/cell-matrix adhesive properties. Atomic force microscopy (AFM) directly demonstrates that Plexin-B2 modulates cell stiffness in hESC colonies, which in turn impacts cell proliferation and cell fate specification through β-catenin signaling and YAP mechanosensing. YAP also functions as a mechanoregulator downstream of Plexin-B2, thus forming a mechanochemical integrative loop. In human neuroprogenitor cells (hNPCs), Plexin-B2 similarly controls cell stiffness and tensile forces, as revealed by AFM and FRET tension sensor studies. Strikingly, Plexin-B2-deficient hNPCs display accelerated neuronal differentiation. From an organogenesis perspective, Plexin-B2 maintains cytoarchitectural integrity of neuroepithelium, as modeled in cerebral organoids. On a signaling level, Plexin-B2 engages extracellular as well as intracellular Ras-GAP and RBD domains for mechanoregulation through Rap and Rac GTPases. Our data unveil a fundamental function of Plexin-B2 for mechanochemical integration during multicellular organization, and shed light on the principle of force-mediated regulation of stem cell biology and tissue morphogenesis.
- Open Access
- 1 April 2019
- Published by Elsevier in EBioMedicine
- Vol. 42, 252-269
Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment
- 1 April 2019
- Published by Elsevier in EBioMedicine
- Vol. 42, 252-269
Open AccessGene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment
- Open Access
- 1 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
The intrinsic drivers of migration in glioblastoma (GBM) are poorly understood. To better capture the native molecular imprint of GBM and its developmental context, here we isolate human stem cell populations from GBM (GSC) and germinal matrix tissues and map their chromatin accessibility via ATAC-seq. We uncover two distinct regulatory GSC signatures, a developmentally shared/proliferative and a tumor-specific/migratory one in which TEAD1/4 motifs are uniquely overrepresented. Using ChIP-PCR, we validate TEAD1 trans occupancy at accessibility sites within AQP4, EGFR, and CDH4. To further characterize TEAD’s functional role in GBM, we knockout TEAD1 or TEAD4 in patient-derived GBM lines using CRISPR-Cas9. TEAD1 ablation robustly diminishes migration, both in vitro and in vivo, and alters migratory and EMT transcriptome signatures with consistent downregulation of its target AQP4. TEAD1 overexpression restores AQP4 expression, and both TEAD1 and AQP4 overexpression rescue migratory deficits in TEAD1-knockout cells, implicating a direct regulatory role for TEAD1–AQP4 in GBM migration.
- 1 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Open AccessAnalysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
The intrinsic drivers of migration in glioblastoma (GBM) are poorly understood. To better capture the native molecular imprint of GBM and its developmental context, here we isolate human stem cell populations from GBM (GSC) and germinal matrix tissues and map their chromatin accessibility via ATAC-seq. We uncover two distinct regulatory GSC signatures, a developmentally shared/proliferative and a tumor-specific/migratory one in which TEAD1/4 motifs are uniquely overrepresented. Using ChIP-PCR, we validate TEAD1 trans occupancy at accessibility sites within AQP4, EGFR, and CDH4. To further characterize TEAD’s functional role in GBM, we knockout TEAD1 or TEAD4 in patient-derived GBM lines using CRISPR-Cas9. TEAD1 ablation robustly diminishes migration, both in vitro and in vivo, and alters migratory and EMT transcriptome signatures with consistent downregulation of its target AQP4. TEAD1 overexpression restores AQP4 expression, and both TEAD1 and AQP4 overexpression rescue migratory deficits in TEAD1-knockout cells, implicating a direct regulatory role for TEAD1–AQP4 in GBM migration.
- Open Access
- 1 May 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (5) , 1421-1429
Prospective Isolation and Comparison of Human Germinal Matrix and Glioblastoma EGFR + Populations with Stem Cell Properties
- 1 May 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 8 (5) , 1421-1429
Open AccessProspective Isolation and Comparison of Human Germinal Matrix and Glioblastoma EGFR + Populations with Stem Cell Properties
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4238
PIWI proteins as prognostic markers in non small cell lung cancer
PiwiRNA (piRNA) are a recently discovered class of small RNAs which binds to PIWI proteins. Until recently, their expression was believed to be limited to germinal stem cells. However, piRNA expression has now been identified in somatic cells and especially in tumor cells. We aim to explore the relationship between the activation of the piRNA pathway and the prognosis of non-small cell lung carcinoma (NSCLC). Design: We studied prospectively 71 surgically resected NSCLC patients from 2007 to 2011. We assessed the expression of the four PIWI proteins: PIWIL1-4; both in normal and tumor tissue by RT-PCR (frozen tissue) and also by immunohistochemical techniques (FFPE tissue). The expression levels were correlated with patient outcome: disease free survival (DFS) and the overall survival (OS). Results: The quantification of the mRNA levels of the four PIWI proteins showed first that PIWIL1 where not expressed in any normal tissue, but its expression was detected in 11 tumor samples. Interestingly, the prognosis analysis showed that the 11 patients expressing PIWIL1 had worse DFS (20 vs 50 months; p=0.0078) and shorter OS (32 vs 61 months; p=0.0076). These results were validated by immunochemistry, with a faintly cytoplasmic reactivity in the positive cases. Second, PIWIL3 were not expressed neither in normal lung tissue nor tumor tissue. Third, PIWIL2 and PIWIL4 were detected in all the samples. However, both were downregulated in tumor tissue in comparison to the paired normal tissue (pConclusion: The expression of PIWI 1 and 4 could have prognostic significance in NSCLC.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4238
PIWI proteins as prognostic markers in non small cell lung cancer
PiwiRNA (piRNA) are a recently discovered class of small RNAs which binds to PIWI proteins. Until recently, their expression was believed to be limited to germinal stem cells. However, piRNA expression has now been identified in somatic cells and especially in tumor cells. We aim to explore the relationship between the activation of the piRNA pathway and the prognosis of non-small cell lung carcinoma (NSCLC). Design: We studied prospectively 71 surgically resected NSCLC patients from 2007 to 2011. We assessed the expression of the four PIWI proteins: PIWIL1-4; both in normal and tumor tissue by RT-PCR (frozen tissue) and also by immunohistochemical techniques (FFPE tissue). The expression levels were correlated with patient outcome: disease free survival (DFS) and the overall survival (OS). Results: The quantification of the mRNA levels of the four PIWI proteins showed first that PIWIL1 where not expressed in any normal tissue, but its expression was detected in 11 tumor samples. Interestingly, the prognosis analysis showed that the 11 patients expressing PIWIL1 had worse DFS (20 vs 50 months; p=0.0078) and shorter OS (32 vs 61 months; p=0.0076). These results were validated by immunochemistry, with a faintly cytoplasmic reactivity in the positive cases. Second, PIWIL3 were not expressed neither in normal lung tissue nor tumor tissue. Third, PIWIL2 and PIWIL4 were detected in all the samples. However, both were downregulated in tumor tissue in comparison to the paired normal tissue (pConclusion: The expression of PIWI 1 and 4 could have prognostic significance in NSCLC.
- Open Access
- 23 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (31) , 31544-31556
The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer
The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer
- 23 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (31) , 31544-31556
Open AccessThe significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer
The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer The significance of PIWI family expression in human lung embryogenesis and non-small cell lung cancer
- Open Access
- 22 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (3) , 1874-1883
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
- 22 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (3) , 1874-1883
Open AccessA serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma
- Open Access
- 1 January 2015
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (1) , e145
Differential MIR-21 Expression in Plasma From Mesenteric Versus Peripheral Veins
Findings on the role of plasma miR-21 expression in colorectal cancer are contradictory. Before reaching a peripheral vein (PV), microRNAs released by the tumor are dispersed throughout the body. We hypothesized that blood drawn from the mesenteric vein (MV) near the site of the primary tumor could provide more homogeneous information than blood drawn from the PV.We have analyzed miR-21 expression in matched samples of tumor tissue, normal tissue, MV plasma, and PV plasma in 57 surgically resected patients with colon cancer and correlated our findings with clinical characteristics and disease-free survival (DFS).miR-21 expression was higher in MV than PV plasma (P = 0.014) and in tumor than in normal tissue (P < 0.001). Patients with high levels of miR-21 in MV plasma had shorter DFS (P = 0.05) than those with low levels, and those with high levels in both MV and PV plasma had shorter DFS than all other patients (P = 0.01).Our findings suggest that the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression.
- 1 January 2015
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (1) , e145
Open AccessDifferential MIR-21 Expression in Plasma From Mesenteric Versus Peripheral Veins
Findings on the role of plasma miR-21 expression in colorectal cancer are contradictory. Before reaching a peripheral vein (PV), microRNAs released by the tumor are dispersed throughout the body. We hypothesized that blood drawn from the mesenteric vein (MV) near the site of the primary tumor could provide more homogeneous information than blood drawn from the PV.We have analyzed miR-21 expression in matched samples of tumor tissue, normal tissue, MV plasma, and PV plasma in 57 surgically resected patients with colon cancer and correlated our findings with clinical characteristics and disease-free survival (DFS).miR-21 expression was higher in MV than PV plasma (P = 0.014) and in tumor than in normal tissue (P < 0.001). Patients with high levels of miR-21 in MV plasma had shorter DFS (P = 0.05) than those with low levels, and those with high levels in both MV and PV plasma had shorter DFS than all other patients (P = 0.01).Our findings suggest that the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression.
- Open Access
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 2045
Salvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways
Introduction: Multiple myeloma (MM) remains an incurable disease for most patients. Thus, sequential therapy when relapse or progression after first line is almost always needed. Immunomodulatory agents derived from thalidomide such as lenalidomide, has several antitumoral effects including anti-proliferative and immune-modulation by binding the intracellular protein cereblon. Lenalidomide has been approved for the treatment of relapsed or refractory MM in Europe and USA. The possibility of using biological predictors of response with this regimen could be promising. A group of genetic normal variations in DNA, mainly single nucleotide polymorphisms (SNPs), have been described in association with response to treatment in MM. A distinctive group of polymorphisms is constituted by SNPs in microRNAs (miRNA) processing machinery in miRNA precursor molecules and in miRNA binding sites, known as miRSNPs, that we have associated with response to autologous transplantation and bortezomib. The aim of this study was to ascertain the outcome of patients with relapsed myeloma treated with lenalidomide in a tertiary hospital as to investigate the prognostic impact of 9 miRSNPs located either in MM related miRNAs target genes or in miRNA biogenesis pathway proteins Methods: One hundred and three patients (54M/49F; median age 65 years, range 30 to 86) with relapsed MM after at least one treatment regimen were treated from November 2003 to January 2014 with lenalidomide plus dexamethasone. Median follow-up for alive patients was 3 years. Patients had received a median number of 2 treatment lines (range 1 – 6), but with no lenalidomide-based regimens. Genomic DNA was isolated from bone marrow slides using a commercial kit (Qiagen). The genes and SNPs evaluated in genomic DNA by allelic discrimination (TaqMan assays) were KRT81 (rs3660), FAM179b (rs1053667), MIR146A (rs2910164), MIR196A2 (rs11614913), MIR149 (rs2292832) and MIR423 (rs6505162) for miRNA target genes, and RAN (rs14035), TRBP (rs784567) and XPO5 (rs11077) for miRNA biogenesis pathway. These genes were selected based on their potential impact on prognosis in solid tumors in previous reports. Results: Overall response (OR) was achieved in 55.4% of the patients (complete remission 6.8%, partial response 40.8% and minor response 7.8%), while 16 (15.5%) and 26 (25.2%) showed no response (NR) or progressive disease (PD), respectively. 4 patients (3.9%) died before response could be evaluated. The median progression-free survival (PFS) after lenalidomide therapy was 8.1 months (95% CI 7.3 to 8.9), with a median overall survival (OS) of 2.3 years (95% CI 1.5 to 3.2). OS was significantly shorter in those patients not reaching at least MR (1 vs. 3.7 years; pFAM179b (p=0.041) (Figure 1) and MIR196A2 (p=0.01) (Figure 2), with a trend for MIR149 (p=0.117). In the two first SNPs, there were also a significant impact in PFS after lenalidomide regimen (p=0.024 and p=0.018). Interestingly, these miRSNPs have not shown the same impact as previously reported when autologous transplantation or bortezomib are used, where XPO5 is the crucial gene. Other factors associated with longer OS included lenalidomide at first relapse vs. subsequent lines (p=0.002), IgG isotype (p=0.044), normal serum LDH (p=0.032) and a trend for creatinine lower than 2 mg/dL (p=0.08) at diagnosis. In a multivariate analysis for OS, only the use of lenalidomide at first relapse (HR 2, 95% IC 1.04-3.9; p=0.039) and SNP in MIR196A2 (HR 1.86, 95% IC 1.03-3.4; p=0.04) remained at significant level. Conclusions: Lenalidomide plus dexamethasone is a very active regimen when used in daily clinical practice, particularly at the time of first relapse. A small subgroup of patients can remain disease-free for more than 5 years. Some SNPs in miRNA target genes (FAM179b and, particularly, MIR196A) could be useful as potential predictors of response.
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 2045
Open AccessSalvage Therapy for Multiple Myeloma with Lenalidomide-Based Regimens: Impact of Single Nucleotide Polymorphisms Related to miRNA Pathways
Introduction: Multiple myeloma (MM) remains an incurable disease for most patients. Thus, sequential therapy when relapse or progression after first line is almost always needed. Immunomodulatory agents derived from thalidomide such as lenalidomide, has several antitumoral effects including anti-proliferative and immune-modulation by binding the intracellular protein cereblon. Lenalidomide has been approved for the treatment of relapsed or refractory MM in Europe and USA. The possibility of using biological predictors of response with this regimen could be promising. A group of genetic normal variations in DNA, mainly single nucleotide polymorphisms (SNPs), have been described in association with response to treatment in MM. A distinctive group of polymorphisms is constituted by SNPs in microRNAs (miRNA) processing machinery in miRNA precursor molecules and in miRNA binding sites, known as miRSNPs, that we have associated with response to autologous transplantation and bortezomib. The aim of this study was to ascertain the outcome of patients with relapsed myeloma treated with lenalidomide in a tertiary hospital as to investigate the prognostic impact of 9 miRSNPs located either in MM related miRNAs target genes or in miRNA biogenesis pathway proteins Methods: One hundred and three patients (54M/49F; median age 65 years, range 30 to 86) with relapsed MM after at least one treatment regimen were treated from November 2003 to January 2014 with lenalidomide plus dexamethasone. Median follow-up for alive patients was 3 years. Patients had received a median number of 2 treatment lines (range 1 – 6), but with no lenalidomide-based regimens. Genomic DNA was isolated from bone marrow slides using a commercial kit (Qiagen). The genes and SNPs evaluated in genomic DNA by allelic discrimination (TaqMan assays) were KRT81 (rs3660), FAM179b (rs1053667), MIR146A (rs2910164), MIR196A2 (rs11614913), MIR149 (rs2292832) and MIR423 (rs6505162) for miRNA target genes, and RAN (rs14035), TRBP (rs784567) and XPO5 (rs11077) for miRNA biogenesis pathway. These genes were selected based on their potential impact on prognosis in solid tumors in previous reports. Results: Overall response (OR) was achieved in 55.4% of the patients (complete remission 6.8%, partial response 40.8% and minor response 7.8%), while 16 (15.5%) and 26 (25.2%) showed no response (NR) or progressive disease (PD), respectively. 4 patients (3.9%) died before response could be evaluated. The median progression-free survival (PFS) after lenalidomide therapy was 8.1 months (95% CI 7.3 to 8.9), with a median overall survival (OS) of 2.3 years (95% CI 1.5 to 3.2). OS was significantly shorter in those patients not reaching at least MR (1 vs. 3.7 years; pFAM179b (p=0.041) (Figure 1) and MIR196A2 (p=0.01) (Figure 2), with a trend for MIR149 (p=0.117). In the two first SNPs, there were also a significant impact in PFS after lenalidomide regimen (p=0.024 and p=0.018). Interestingly, these miRSNPs have not shown the same impact as previously reported when autologous transplantation or bortezomib are used, where XPO5 is the crucial gene. Other factors associated with longer OS included lenalidomide at first relapse vs. subsequent lines (p=0.002), IgG isotype (p=0.044), normal serum LDH (p=0.032) and a trend for creatinine lower than 2 mg/dL (p=0.08) at diagnosis. In a multivariate analysis for OS, only the use of lenalidomide at first relapse (HR 2, 95% IC 1.04-3.9; p=0.039) and SNP in MIR196A2 (HR 1.86, 95% IC 1.03-3.4; p=0.04) remained at significant level. Conclusions: Lenalidomide plus dexamethasone is a very active regimen when used in daily clinical practice, particularly at the time of first relapse. A small subgroup of patients can remain disease-free for more than 5 years. Some SNPs in miRNA target genes (FAM179b and, particularly, MIR196A) could be useful as potential predictors of response.
- 1 August 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (8) , 874-881
High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome
- 1 August 2014
- Published by Elsevier in Leukemia Research
- Vol. 38 (8) , 874-881
High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome